ORKA-021

**ORKA-021** is an investigational sequential biologic regimen developed by Oruka Therapeutics for psoriatic disease. It administers the half-life-extended anti-IL-17A/F monoclonal antibody ORKA-002 first to induce rapid and deep disease responses, followed by the half-life-extended anti-IL-23p19 monoclonal antibody ORKA-001 for durable maintenance. The regimen is intended for plaque psoriasis and psoriatic arthritis, combining IL-17A/F neutralization with IL-23p19 inhibition. ([ir.orukatx.com](https://ir.orukatx.com/news-releases/news-release-details/oruka-therapeutics-reports-second-quarter-2025-financial-results))

Other names

ORKA 021ORKA021ORKA-021ORKA-002 + ORKA-001ORKA-002 → ORKA-001Sequential combination regimen of ORKA-002 and ORKA-001